Unibest
← Back to patent-cliff list

CAS 158966-92-8

(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid

Codes: MONT-014

Application context (from source-drug indications)

Allergic rhinitisMontelukastAsthmaMontelukastHypersensitivity reactionMontelukastSeasonal allergic rhinitisMontelukastPerennial allergic rhinitisMontelukastExercise-induced asthmaMontelukast

Source drugs (routes using this intermediate)

DrugTierExpiry
MontelukastTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

MontelukastOptimised routesteps: 5total yield: 33.50 g
(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid→methyl (R,E)-2-(3-(acetylthio)-3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)propyl)benzoate→(R,E)-2-(2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-mercaptopropyl)phenyl)propan-2-ol ((4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate→methyl 2-(1-(bromomethyl)cyclopropyl)acetate→methyl (R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate→diisobutylamine 2-(1-((((R)-1-(3-((E)-2-((E)-6-(2-chloroethylidene)-5,6-dihydropyridin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.